Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 13 | 2021 | 1426 | 0.900 |
Why?
|
| Phyllodes Tumor | 1 | 2015 | 1 | 0.540 |
Why?
|
| Upper Extremity | 2 | 2018 | 7 | 0.310 |
Why?
|
| Lymphedema | 1 | 2020 | 4 | 0.200 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 75 | 0.200 |
Why?
|
| Students, Medical | 1 | 2021 | 121 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 40 | 0.180 |
Why?
|
| Quality of Health Care | 2 | 2010 | 136 | 0.170 |
Why?
|
| Mastectomy, Segmental | 2 | 2016 | 18 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2021 | 1961 | 0.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2015 | 9 | 0.160 |
Why?
|
| Mastectomy | 1 | 2018 | 19 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 964 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 25 | 0.140 |
Why?
|
| Middle Aged | 10 | 2018 | 9642 | 0.140 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 13 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 32 | 0.130 |
Why?
|
| Aged | 8 | 2015 | 6448 | 0.130 |
Why?
|
| Hospitals, Public | 2 | 2015 | 12 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2016 | 206 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 231 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 133 | 0.130 |
Why?
|
| Female | 12 | 2021 | 19873 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 249 | 0.120 |
Why?
|
| Humans | 16 | 2021 | 34853 | 0.110 |
Why?
|
| Angiomatosis | 1 | 2012 | 1 | 0.110 |
Why?
|
| Breast Diseases | 1 | 2012 | 6 | 0.110 |
Why?
|
| Adult | 8 | 2018 | 11034 | 0.110 |
Why?
|
| Hyperplasia | 1 | 2012 | 38 | 0.110 |
Why?
|
| Carcinoma | 1 | 2013 | 94 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 78 | 0.110 |
Why?
|
| Prognosis | 3 | 2020 | 707 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 145 | 0.100 |
Why?
|
| Breast | 1 | 2012 | 134 | 0.100 |
Why?
|
| Mammography | 2 | 2012 | 176 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2005 | 413 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2018 | 1353 | 0.080 |
Why?
|
| Patient Advocacy | 1 | 2008 | 20 | 0.080 |
Why?
|
| Arm | 2 | 2020 | 25 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 247 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2008 | 122 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 90 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2008 | 202 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 901 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 446 | 0.070 |
Why?
|
| Health Education | 1 | 2008 | 304 | 0.070 |
Why?
|
| Gene Products, nef | 1 | 2005 | 19 | 0.070 |
Why?
|
| Mass Screening | 1 | 2008 | 427 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 165 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 2333 | 0.050 |
Why?
|
| Physical Examination | 1 | 2021 | 40 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 32 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 269 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 27 | 0.050 |
Why?
|
| Learning | 1 | 2021 | 108 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2021 | 89 | 0.050 |
Why?
|
| Curriculum | 1 | 2021 | 237 | 0.050 |
Why?
|
| Hospitals, Urban | 2 | 2008 | 38 | 0.040 |
Why?
|
| Medical Oncology | 2 | 2008 | 26 | 0.040 |
Why?
|
| Axilla | 1 | 2016 | 8 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 10 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 30 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2561 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2016 | 64 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 161 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 841 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 210 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 207 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 1003 | 0.030 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 531 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2013 | 7 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 15 | 0.030 |
Why?
|
| Perimenopause | 1 | 2012 | 4 | 0.030 |
Why?
|
| Young Adult | 2 | 2012 | 4012 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 5035 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 15 | 0.020 |
Why?
|
| Community Networks | 1 | 2008 | 98 | 0.020 |
Why?
|
| Social Class | 1 | 2008 | 228 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 628 | 0.020 |
Why?
|
| Social Support | 1 | 2008 | 356 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 36 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 87 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2005 | 143 | 0.020 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 51 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 86 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 1425 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 580 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 328 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 790 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1149 | 0.010 |
Why?
|
| HIV-1 | 1 | 2005 | 678 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1317 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 5668 | 0.010 |
Why?
|
| Male | 1 | 2012 | 18870 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 14307 | 0.010 |
Why?
|